The 36 references in paper O. Shakhmatova O., E. Panchenko P., О. Шахматова О., Е. Панченко П. (2017) “АПИКСАБАН В ЛЕЧЕНИИ ФИБРИЛЛЯЦИИ ПРЕДСЕРДИЙ: РАНДОМИЗИРОВАННЫЕ ИССЛЕДОВАНИЯ И ПОВСЕДНЕВНАЯ КЛИНИЧЕСКАЯ ПРАКТИКА // APIXABAN IN THE TREATMENT OF ATRIAL FIBRILLATION: RANDOMIZED TRIALS AND EVERYDAY CLINICAL PRACTICE” / spz:neicon:aterotromboz:y:2017:i:1:p:67-77

1
Fauchier L, Philippart R, Clementy N, et al.How to define valvular atrial fibrillation? Arch Cardiovasc Dis,
(check this in PDF content)
2
15, 108: 530–539. 2. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: a major contributor to stroke in the elderly: the Framingham Study. Arch Intern Med,1987, 147: 1561–1564.
(check this in PDF content)
3
P Kirchhof, S Benussi, D Kotecha, etal. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Heart Journal. doi: 10.1093/eurheartj/ehw210.
(check this in PDF content)
4
Evaluation of prescribing with NOACs vs VKAs in nonvalvular AF. Доклад Sylvia Haas на Европейском Конгрессе Кардиологов 2016, Рим. https: //www.youtube.com/watch?v = xSrsxJd7tJM.
(check this in PDF content)
5
Camm AJ, Accetta G, Ambrosio G, et al. Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation. Heart, 2017 Feb 15, 103(4): 307-314. doi: 10.1136/heartjnl-2016-309832. Epub 2016 Sep 19.
(check this in PDF content)
6
www.imshealth.com.
(check this in PDF content)
7
Granger CB, Alexander JH, McMurray JJV et al. Apixaban versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med,2011, 365: 981-992.
(check this in PDF content)
8
Wallentin L, Lopes RD, Hanna M et al. Efficacy and Safety of Apixaban Compared with Warfarin at Different Levels of Predicted INR Control for Stroke Prevention in Atrial Fibrillation. Circulation, 2013, 127: 2166-2176.
(check this in PDF content)
9
Easton JD, Lopes RD, Bahit M, et al. Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial. The Lancet Neurology, 2012, 11(6): 503-511.
(check this in PDF content)
10
Alexander JH, Lopes RD, Thomas L et al. Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial. European Heart Journal, 2014, 35: 224–232.
(check this in PDF content)
11
Bahit MC, Lopes RD, Wojdyla DM, et al. Non-major bleeding with apixaban versus warfarin in patients with atrial fibrillation. Heart Online First, published on October 24, 2016 as 10.1136/heartjnl-2016-309901.
(check this in PDF content)
12
Flaker G, Lopes RD, Al-Khatib SM, et al. Efficacy and safety ofapixaban in patients after cardioversion for atrial fibrillation: insightsfrom the ARISTOTLE trial (Apixaban for Reduction in Stroke andOther Thromboembolic Events in Atrial Fibrillation). J Am Coll Cardiol,2014, 63: 1082–7.
(check this in PDF content)
13
Flaker G, Lopes RD, Hylek E, et al. Amiodarone, anticoagulation, and clinical events in patients with atrial fibrillation: insights from the ARISTOTLE trial. J Am Coll Cardiol, 2014 Oct 14, 64(15): 1541-50. doi: 10.1016/j.jacc.2014.07.967.
(check this in PDF content)
14
Held C, Hylek EM, Alexander JH, et al. Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial. Eur Heart J, 2015 May 21, 36(20): 1264-72. doi: 10.1093/eurheartj/ehu463.
(check this in PDF content)
15
Focks JJ, Brouwer MA, Wojdyla DM, et al. Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: post hoc analysis of the ARISTOTLE trial. BMJ, 2016, 353: i2868. Published online 2016 Jun 15. doi: 10.1136/bmj.i2868.
(check this in PDF content)
16
Melloni C, Dunning A, Granger CB et al. Efficacy and safety of apixaban versus warfarin in patients with atrial fibrillation and active cancer: insights from the ARISTOTLE trial. Paper presented at Congress of the European-Society-of-Cardiology (ESC), AUG 27-31, 2016, Rome, ITALY, pp. 234-234.
(check this in PDF content)
17
Xavier D, Hanna M, Wallentin L et al. Patients with atrial fibrillation treated with apixaban are less likely to discontinue study drug when compared with warfarin: insights from the ARISTOTLE trial. Paper presented at Congress of the European-Society-ofCardiology (ESC), AUG 27-31, 2016, Rome, ITALY, pp. 507-507.
(check this in PDF content)
18
Westenbrink B, Alings M, Granger CB.,et al. Anemia Is Associated With Bleeding and Mortality, but Not Stroke, in Patients With Atrial Fibrillation: Insights From the ARISTOTLE Trial. American Heart Journal, 2016. doi: 10.1016/j.ahj.2016.12.008.
(check this in PDF content)
19
Hu PT, Lopes RD, Stevens SR, et al. Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation and Peripheral Artery Disease: Insights From the ARISTOTLE Trial. JAHA,2017, 6: e004699. originally published January 17, 2017. https: //doi.org/10.1161/JAHA.116.004699.
(check this in PDF content)
20
Guimara~es PO, Wojdyla DM, Alexander JH, et al. Anticoagulation therapy and clinical outcomes in patients with recently diagnosed atrial fibrillation: Insights from the ARISTOTLE trial. Int J Cardiol, 2017 Jan 15, 227: 443-449. doi: 10.1016/j.ijcard.2016.11.014.
(check this in PDF content)
21
Hohnloser SH, Hijazi Z, Thomas L, et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J, 2012, 33(22): 2821-2830.
(check this in PDF content)
22
Hijazi Z, Hohnloser SH, Andersson U, et al. Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation in Relation to Renal Function Over Time: Insights From the ARISTOTLE Randomized Clinical Trial. JAMA Cardiol, 2016, 1(4): 451-460. doi: 10.1001/jamacardio.2016.1170.
(check this in PDF content)
23
Лукьянов М.М., Бойцов С.А., Якушин C.C. и др. Диагностика, лечение, сочетанная сердечно-сосудистая патология и сопутствующие заболевания у больных с диагнозом «фибрилляция предсердий» в условиях реальной амбулаторно-поликлинической практики (по данным регистра кардиоваскулярных заболеваний РЕКВАЗА). Рациональная Фармакотерапия в Кардиологии, 2014, 10(4): 36677.24)
(check this in PDF content)
24
Bahit MC, Lopes RD, Wojdyla DM, et al. Apixaban in patients with atrial fibrillation and prior coronary artery disease: insights from the ARISTOTLE trial. Int J Cardiol, 2013 Dec 10, 170(2): 215-20. doi: 10.1016/j.ijcard.2013.10.062.
(check this in PDF content)
25
Larsen TB, Skjoth F, Nielsen PB, Kjaeldgaard JN, Lip GY. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ,2016, 353: i3189.
(check this in PDF content)
26
Lip GY, Keshishian A, Kamble S, et al. Real-world comparison of major bleeding risk among non- valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin. A propensity score matched analysis. Thromb Haemost, 2016 Oct 28, 116(5): 975-986.
(check this in PDF content)
27
Lamberts M, Staerk L, Olesen JB, et al. Major Bleeding Complications and Persistence With Oral Anticoagulation in Non-Valvular Atrial Fibrillation: Contemporary Findings in Real-Life Danish Patients. J Am Heart Assoc, 2017 Feb 14, 6(2): e004517. doi: 10.1161/JAHA.116.004517.
(check this in PDF content)
28
Deitelzweig S, Bruno A, Trocio J, et al. An early evaluation of bleeding-related hospital readmissions among hospitalized patients with nonvalvular atrial fibrillation treated with direct oral anticoagulants. Current Medical Research And Opinion, 2016, 32(3).
(check this in PDF content)
29
Raschi E, Bianchin M, Ageno W, et al. Risk-Benefit Profile of Direct-Acting Oral Anticoagulants in Established Therapeutic Indications: An Overview of Systematic Reviews and Observational Studies. Drug Saf,2016, 39: 1175–1187.
(check this in PDF content)
30
Freedman B, Potpara TS, Lip GYH. Stroke prevention in atrial fibrillation. The Lancet, 2016, 388(10046): 806-817.
(check this in PDF content)
31
Diener HC, Aisenberg J, Ansell J, et al. Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with nonvalvular atrial fibrillation: part 1. Eur Heart J. doi: 10.1093/eurheartj/ehv643. (Epub 4 Feb 2016).
(check this in PDF content)
32
Diener HC, Aisenberg J, Ansell J, et al. Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with nonvalvular atrial fibrillation: part 2. Eur Heart J,doi: 10.1093/eurheartj/ehw069. (Epub 4 Feb 2016).
(check this in PDF content)
33
Ukaigwe A, Shrestha P, Karmacharya P, et al. Metaanalysis of efficacy and safety of apixaban and uninterrupted apixaban therapy compared to vitamin K antagonists inpatients undergoing catheter ablation for atrial fibrillation. J Interv Card Electrophysiol, 2017 Mar, 48(2): 223-233. doi: 10.1007/s10840-016-01955.
(check this in PDF content)
34
Heidbuchel H, Verhamme P, Alings M, et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace, 2015 Oct, 17(10): 1467-507. doi: 10.1093/europace/euv309.
(check this in PDF content)
35
Wang X, Tirucherai G, Marbury TC, et al. Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end-stage renal disease on hemodialysis. J Clin Pharmacol, 2016 May, 56(5): 628-
(check this in PDF content)
36
doi: 10.1002/jcph.628. 36. Lester PA, Coleman DM, Diaz JA, et al. ApixabanVersusWarfarinfor Mechanical Heart Valve Thromboprophylaxis in a Swine Aortic Heterotopic Valve Model. https: //doi.org/10.1161/ATVBA-
(check this in PDF content)